Side-by-side · Research reference

ProstamaxvsThymosin α-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED11/38 cited

BPhase 3HUMAN-REVIEWED8/39 cited

Prostamax

Khavinson Bioregulator · Tissue-Specific Peptide

0.05 ng/mLActive concentrationZakutskiĭ 2006

2.5×SCE frequency increaseDzhokhadze 2012

4 AAPeptide length

SQ · Protocol per Khavinson tradition

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

01Mechanism of Action

Parameter

Prostamax

Thymosin α-1

Primary target

Chromatin in prostatic cells — pericentromeric heterochromatin regions

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Pathway

Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

Downstream effect

Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012 Zakutskiĭ 2006

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Feedback intact?

—

Origin

Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Antibody development

—

02Dosage Protocols

Parameter

Prostamax

Thymosin α-1

Effective concentration (in vitro)

0.05 ng/mLZakutskiĭ 2006

Organotypic culture model; demonstrated tissue-specific stimulation.

—

Human clinical dose

Not established

No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).

—

Evidence basis

Animal / organotypic cultureZakutskiĭ 2006 Dzhokhadze 2012

No randomized controlled trials in humans.

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Age groups studied

Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006 Dzhokhadze 2012

—

Duration

Not specified

Khavinson protocols typically 10–20 days per cycle; no long-term safety data.

6–12 months for chronic indications

Standard dose (HBV/HCV)

—

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

Frequency

—

2× weekly (Mon/Thu typical)

Lower / starter dose

—

0.8 mg per injection

Reconstitution

—

Sterile water for injection per vial label

Timing

—

No specific time

Half-life

—

~2 hours plasma; tissue effect days

04Side Effects & Safety

Parameter

Prostamax

Thymosin α-1

Published adverse events

None reported in available literature

—

Genotoxicity signals

Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications

—

Metal ion interactions

Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance

—

Human safety data

Absent — no published Phase 1/2/3 trials

—

Injection site reaction

—

Erythema, mild discomfort

GI symptoms

—

Rare nausea

Fatigue

—

Common during initial weeks

Fever / flu-like

—

Mild interferon-like response possible

Autoimmune

—

Theoretical risk; caution in active autoimmune disease

Cancer risk

—

No signal — used as adjuvant in oncology

Pregnancy / OB

—

Avoid

Absolute Contraindications

Prostamax

·Active prostate malignancy — epigenetic modulation effects unknown in cancer

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Relative Contraindications

Prostamax

·History of prostate cancer — theoretical concern re: transcriptional activation
·Undiagnosed prostatic nodules or elevated PSA

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

05Administration Protocol

Parameter

Prostamax

Thymosin α-1

1. Route

Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

2. Reconstitution

If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Frequency

Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.

2× weekly, e.g. Monday + Thursday.

4. Monitoring

No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

5. Note

All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.

27–31G, 4–8 mm insulin syringe.